Xspray Pharma AB ((DE:6XP)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xspray Pharma AB has recently completed a clinical study titled An Open-label, Single-center, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Study to Evaluate the Oral Comparative Bioavailability of XS003 (Nilotinib) Capsules 192 mg Under Fasted and Fed Conditions in Healthy, Adult Subjects. The primary objective of this study was to assess the bioavailability of XS003 (nilotinib) under different dietary conditions, which is crucial for optimizing its therapeutic efficacy.
The study tested XS003, a drug designed to improve the bioavailability of nilotinib, a treatment option for certain types of cancer. The intervention involved administering XS003 in both fasted and fed states to evaluate its absorption and effectiveness.
This interventional study followed a randomized, crossover design without masking, focusing on treatment as its primary purpose. Participants were randomly assigned to receive the drug under different conditions, ensuring a comprehensive comparison of its bioavailability.
The study commenced on October 3, 2024, with primary completion achieved by July 29, 2025. The latest update was submitted on August 20, 2025. These dates are significant as they mark the progression and timely updates of the study, reflecting its adherence to planned timelines.
The completion of this study could have positive implications for Xspray Pharma AB’s stock performance, as successful results may enhance investor confidence and position the company competitively within the pharmaceutical industry. The study’s outcomes could influence market dynamics, especially if XS003 proves to be a superior formulation of nilotinib.
The study is now completed, with further details available on the ClinicalTrials portal.